Geode Capital Management, LLC Madrigal Pharmaceuticals, Inc. Transaction History

Geode Capital Management, LLC

$1.07 Trillion
Q1 2024

A detailed history of Geode Capital Management, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 346,857 shares of MDGL stock, worth $94.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

346,857

Previous 336,255 3.15%

Holding current value

$94.2 Million

Previous $77.8 Million 19.05%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$171.37 - $283.23 $1.82 Million - $3 Million	10,602 Added 3.15%	346,857 $92.6 Million
Q4 2023 Feb 13, 2024	BUY	$120.4 - $237.13 $4.79 Million - $9.44 Million	39,817 Added 13.43%	336,255 $77.8 Million
Q3 2023 Nov 13, 2023	BUY	$146.04 - $225.78 $3.67 Million - $5.67 Million	25,119 Added 9.26%	296,438 $43.3 Million
Q2 2023 Aug 11, 2023	BUY	$203.88 - $312.0 $4.74 Million - $7.26 Million	23,262 Added 9.38%	271,319 $62.7 Million
Q1 2023 May 15, 2023	BUY	$231.06 - $307.08 $2.65 Million - $3.52 Million	11,472 Added 4.85%	248,057 $60.1 Million

Q4 2022 Feb 13, 2023	BUY	$58.39 - $296.54 $396,993 - $2.02 Million	6,799 Added 2.96%	236,585 $68.7 Million
Q3 2022 Nov 14, 2022	BUY	$60.57 - $79.51 $301,880 - $396,277	4,984 Added 2.22%	229,786 $14.9 Million
Q2 2022 Aug 12, 2022	BUY	$58.04 - $100.2 $395,484 - $682,762	6,814 Added 3.13%	224,802 $16.1 Million
Q1 2022 May 13, 2022	SELL	$55.89 - $101.89 $113,456 - $206,836	-2,030 Reduced 0.92%	217,988 $21.4 Million
Q4 2021 Feb 11, 2022	BUY	$72.34 - $95.09 $1.28 Million - $1.68 Million	17,643 Added 8.72%	220,018 $18.6 Million
Q3 2021 Nov 12, 2021	BUY	$78.35 - $105.02 $334,632 - $448,540	4,271 Added 2.16%	202,375 $16.1 Million
Q2 2021 Aug 13, 2021	BUY	$97.2 - $137.59 $4.21 Million - $5.96 Million	43,308 Added 27.98%	198,104 $19.3 Million
Q1 2021 May 12, 2021	BUY	$108.54 - $125.2 $1.39 Million - $1.6 Million	12,790 Added 9.01%	154,796 $18.1 Million
Q4 2020 Feb 12, 2021	BUY	$110.06 - $133.7 $438,038 - $532,126	3,980 Added 2.88%	142,006 $15.8 Million
Q3 2020 Nov 13, 2020	SELL	$99.78 - $124.21 $76,231 - $94,896	-764 Reduced 0.55%	138,026 $16.4 Million
Q2 2020 Aug 13, 2020	SELL	$60.13 - $125.71 $7,816 - $16,342	-130 Reduced 0.09%	138,790 $15.7 Million
Q1 2020 May 14, 2020	BUY	$66.76 - $93.49 $1 Million - $1.4 Million	14,987 Added 12.09%	138,920 $9.27 Million
Q4 2019 Feb 13, 2020	BUY	$84.28 - $118.5 $1.01 Million - $1.43 Million	12,032 Added 10.75%	123,933 $11.3 Million
Q3 2019 Nov 12, 2019	BUY	$84.4 - $106.53 $205,345 - $259,187	2,433 Added 2.22%	111,901 $9.65 Million
Q2 2019 Aug 14, 2019	BUY	$91.13 - $142.5 $901,731 - $1.41 Million	9,895 Added 9.94%	109,468 $11.5 Million
Q1 2019 May 14, 2019	BUY	$103.48 - $143.84 $937,218 - $1.3 Million	9,057 Added 10.01%	99,573 $12.5 Million
Q4 2018 Feb 13, 2019	BUY	$94.77 - $215.54 $429,876 - $977,689	4,536 Added 5.28%	90,516 $10.2 Million
Q3 2018 Nov 13, 2018	BUY	$207.3 - $300.31 $1.24 Million - $1.79 Million	5,964 Added 7.45%	85,980 $18.4 Million
Q2 2018 Aug 14, 2018	BUY	$101.55 - $313.9 $2.9 Million - $8.95 Million	28,514 Added 55.36%	80,016 $22.4 Million
Q1 2018 May 15, 2018	SELL	$93.35 - $149.04 $261,099 - $416,864	-2,797 Reduced 5.15%	51,502 $6.01 Million
Q4 2017 Feb 13, 2018	BUY	$39.35 - $97.37 $720,852 - $1.78 Million	18,319 Added 50.91%	54,299 $4.98 Million
Q3 2017 Nov 14, 2017	BUY	$15.48 - $46.19 $57,895 - $172,750	3,740 Added 11.6%	35,980 $1.62 Million
Q2 2017 Aug 14, 2017	BUY	N/A	32,240	32,240 $524,000

Others Institutions Holding MDGL

# of Institutions

315

Shares Held

20M

Call Options Held

824K

Put Options Held

1.04M

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $4.65B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Madrigal Pharmaceuticals, Inc. Transaction History